trending Market Intelligence /marketintelligence/en/news-insights/trending/S-7yJ-kgziHFWVFsbzJ-LQ2 content esgSubNav
In This List

UroGen Pharma appoints chief medical officer; director steps down

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


UroGen Pharma appoints chief medical officer; director steps down

UroGen Pharma Ltd. said Chaim Hurvitz resigned from the company's board of directors.

The Nasdaq-listed company also appointed Mark Schoenberg as its chief medical officer.

Schoenberg served as a consultant to UroGen since 2013 before becoming the company's medical director in 2015.